MCID: GST044
MIFTS: 55

Gastritis

Categories: Gastrointestinal diseases, Immune diseases, Infectious diseases

Aliases & Classifications for Gastritis

MalaCards integrated aliases for Gastritis:

Name: Gastritis 12 29 54 6 44 15 62 17 71
Acute Gastric Mucosal Erosion 12 71
Erosive Gastropathy 12 71
Erosive Gastritis 12 71
Idiopathic Erosive/hemorrhagic Gastritis 71
Gastritis Erosive 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4029
MeSH 44 D005756
NCIt 50 C26780
SNOMED-CT 67 155711008
ICD10 32 K29.7
UMLS 71 C0017152 C0267112 C2243088 more

Summaries for Gastritis

PubMed Health : 62 About gastritis: The membranes lining the stomach wall protect it from acid and germs. If this protective lining is irritated or damaged, it can become inflamed. Long-lasting inflammations can further damage the stomach lining and lead to stomach (gastric) ulcers. Inflammation of the stomach lining is called gastritis. It is usually caused by certain bacteria or anti-inflammatory medication. There are two kinds of gastritis: acute and chronic. Acute gastritis is typically accompanied by very noticeable stomach and bowel problems that usually go away again on their own after a few days. Chronic gastritis, on the other hand, sometimes goes unnoticed. People may only realize they have it when complications like stomach ulcers arise.

MalaCards based summary : Gastritis, also known as acute gastric mucosal erosion, is related to autoimmune atrophic gastritis and gastritis, familial giant hypertrophic, and has symptoms including dyspepsia and gastric irritation. An important gene associated with Gastritis is GAST (Gastrin), and among its related pathways/superpathways are Innate Immune System and Toll-Like receptor Signaling Pathways. The drugs Sucralfate and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include t cells, neutrophil and pancreas.

Disease Ontology : 12 A stomach disease that is an inflammation of the lining of the stomach.

Wikipedia : 74 Gastritis is inflammation of the lining of the stomach. It may occur as a short episode or may be of a... more...

Related Diseases for Gastritis

Diseases in the Gastritis family:

Autoimmune Gastritis Viral Gastritis
Bacterial Gastritis

Diseases related to Gastritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 760)
# Related Disease Score Top Affiliating Genes
1 autoimmune atrophic gastritis 32.9 GAST CHGA
2 gastritis, familial giant hypertrophic 32.6 TFF2 MUC6 GAST
3 helicobacter pylori infection 32.5 IL1RN IL1B CXCL8 CXCL1
4 atrophic gastritis 32.0 TFF2 S100A8 PTGS2 PGC PGA5 PGA4
5 gastrointestinal ulceration, recurrent, with dysfunctional platelets 31.9 S100A8 PTGS2 HRH2 GAST
6 bile reflux 31.7 S100A8 PTGS2 GAST
7 gastric ulcer 31.5 S100A8 PTGS2 IL1RN IL1B HRH2 GAST
8 peptic ulcer disease 31.5 S100A8 PTGS2 IL1RN IL1B HRH2 GHRL
9 esophagitis 31.5 PTGS2 IL1B HRH2 GAST CXCL8
10 duodenal ulcer 31.3 TLR4 S100A8 IL1RN IL1B HRH2 GAST
11 celiac disease 1 31.2 TLR4 IL1B GHRL GAST CXCL8
12 microinvasive gastric cancer 31.1 TFF2 S100A8 MUC6 GAST
13 peptic esophagitis 31.0 S100A8 PTGS2 IL1B HRH2 GAST CXCL8
14 crohn's disease 31.0 TLR4 S100A8 IL1B DEFA5 CXCL8
15 zollinger-ellison syndrome 31.0 HRH2 GAST CHGA
16 ulcerative colitis 31.0 TLR4 IL1RN IL1B CXCL8
17 gastroenteritis 30.9 IL1RN IL1B HRH2 CXCL8
18 diarrhea 30.9 TLR4 IL1B HRH2 GAST CXCL8
19 toxic shock syndrome 30.9 TLR4 NOS2 IL1RN IL1B CXCL8
20 type 1 diabetes mellitus 30.8 TLR4 NOS2 IL1RN IL1B CXCL8
21 proteasome-associated autoinflammatory syndrome 1 30.8 TLR4 PTGS2 NOS2 IL1RN IL1B CXCL8
22 postgastrectomy syndrome 30.8 GHRL GAST
23 colitis 30.8 TLR4 TFF2 PTGS2 NOS2 IL1RN IL1B
24 lymphoma, mucosa-associated lymphoid type 30.8 TLR4 S100A8 CXCL8
25 gastric cancer 30.8 TFF2 S100A8 PTGS2 PGA5 PGA4 PGA3
26 carcinoid tumors, intestinal 30.7 GAST CHGA
27 cholecystitis 30.7 TLR4 S100A8 MUC6
28 hernia, hiatus 30.7 HRH2 GHRL GAST
29 enterocolitis 30.7 TLR4 CXCL8
30 peritonitis 30.7 TLR4 IL1B CXCL8 CXCL1
31 gastroesophageal reflux 30.7 S100A8 PTGS2 PGC PGA3 IL1RN IL1B
32 crohn's colitis 30.7 NOS2 IL1B DEFA5 CXCL8
33 gastric neuroendocrine neoplasm 30.7 GAST CHGA
34 barrett esophagus 30.6 TFF2 S100A8 PTGS2 MUC6 GAST
35 pharyngitis 30.6 PTGS2 IL1B CXCL8
36 periodontitis 30.6 TLR4 PTGS2 IL1RN IL1B DEFB1 CXCL8
37 neutropenia 30.5 TLR4 IL1RN IL1B CXCL8
38 duodenal gastrinoma 30.5 HRH2 GAST CHGA
39 candidiasis 30.5 TLR4 IL1B DEFB1 CXCL8
40 irritable bowel syndrome 30.5 TLR4 IL1B GHRL CXCL8 CHGA
41 constipation 30.4 PTGS2 NOS2 GHRL GAST CHGA
42 bacterial infectious disease 30.4 TLR4 IL1RN IL1B DEFB1 CXCL8
43 bronchopneumonia 30.4 TLR4 IL1B CXCL8
44 appendicitis 30.3 TLR4 IL1B CXCL8
45 pyelonephritis 30.3 TLR4 IL1B CXCL8
46 osteoarthritis 30.3 PTGS2 IL1RN IL1B CXCL8
47 cystitis 30.2 TLR4 PTGS2 NOS2 CXCL8 CXCL1
48 diabetes mellitus 30.2 TLR4 PTGS2 NOS2 IL1RN IL1B GHRL
49 gastric gastrinoma 30.2 GAST CHGA
50 pouchitis 30.2 TLR4 IL1RN

Graphical network of the top 20 diseases related to Gastritis:



Diseases related to Gastritis

Symptoms & Phenotypes for Gastritis

UMLS symptoms related to Gastritis:


dyspepsia, gastric irritation

Drugs & Therapeutics for Gastritis

PubMed Health treatment related to Gastritis: 62

If you notice that stress , alcohol or nicotine affect your symptoms, you can try to change your diet, stop drinking alcohol, quit smoking and reduce stress in everyday life. If these lifestyle changes are not enough to relieve the symptoms, medication is considered. Gastritis not caused by Helicobacter pylori is usually treated with medication to lower acid levels. Depending on the type and severity of the symptoms, the following drugs can be used: Proton pump inhibitors (PPIs) like omeprazole or pantoprazole reduce the production of stomach acid. H2 blockers such as ranitidine and famotidine also reduce acid production. Antacids like aluminium hydroxide or magnesium hydroxide neutralize the acid already in your stomach . If the gastritis is caused by a Helicobacter infection and is accompanied by noticeable symptoms, it will be treated using a combination of two or three antibiotics and an acid-lowering proton pump inhibitor . If the gastritis is caused by an NSAID painkiller, it is a good idea to consult your doctor about switching to a different painkiller or combining it with an acid-lowering medication. Should an NSAID have to be taken regularly, it is possible to take it along with acid-lowering medication from the start, as a precaution.

Drugs for Gastritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sucralfate Approved Phase 4 54182-58-0
2
Ethanol Approved Phase 4 64-17-5 702
3
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
4
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
5
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
6
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
7
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
8
Metronidazole Approved Phase 4 443-48-1 4173
9
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
10
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
11
Clarithromycin Approved Phase 4 81103-11-9 84029
12
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
13
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
14
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
15
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
16
Cobalamin Experimental Phase 4 13408-78-1 6857388
17
Wormwood Experimental Phase 4
18
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
19 Protective Agents Phase 4
20 Antioxidants Phase 4
21 Vitamins Phase 4
22 Geranylgeranylacetone Phase 4
23 Vitamin B Complex Phase 4
24 Vitamin B 12 Phase 4
25 Vitamin B12 Phase 4
26 Liposomal amphotericin B Phase 4
27 Mugwort Phase 4
28 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
29 Gastrointestinal Agents Phase 4
30 Antacids Phase 4
31 Anti-Ulcer Agents Phase 4
32 Proton Pump Inhibitors Phase 4
33 Cytochrome P-450 Enzyme Inhibitors Phase 4
34 Anti-Infective Agents Phase 4
35 Cytochrome P-450 CYP3A Inhibitors Phase 4
36 Anti-Bacterial Agents Phase 4
37 Anti-Infective Agents, Local Phase 4
38 Antiparasitic Agents Phase 4
39 Antiprotozoal Agents Phase 4
40 Monoamine Oxidase Inhibitors Phase 4
41
Bismuth Phase 4 7440-69-9 16682734 105143
42
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
43
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
44
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
45
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
46
Ondansetron Approved Phase 3 99614-02-5 4595
47
Ofloxacin Approved Phase 3 82419-36-1 4583
48
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
49
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
50
Pantoprazole Approved Phase 3 102625-70-7 4679

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
2 Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Unknown status NCT02175186 Phase 4 ALBIS;Placebo
3 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
4 A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease Completed NCT00534443 Phase 4
5 A Prospective, Randomized, Double-blind, Double-dummy, Sucralfate Controlled, Multicenter Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis Completed NCT01284647 Phase 4 Teprenone capsule and placebo of sucralfate;Sucralfate and placebo of teprenone
6 A Multiple-center, Self-controlled Open Study to Evaluate Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer Completed NCT01190657 Phase 4 Selbex;Selbex
7 A Multicenter, Randomized, Open-label Phase IV Study Exploring Symptom Control Rate in Co-diagnosed NERD and Chronic Gastritis Patients Treated With 8 Weeks Esomeprazole Treatment Regimen and 2 Weeks Esomeprazole Treatment Regimen Completed NCT01119768 Phase 4 Esomeprazole;Esomeprazole
8 A Phase IV Study to Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis Completed NCT01474044 Phase 4 Gastropylor Complex Capsules
9 A Multicenter, Active-controlled, Randomized, Double-blind Paralleled-group Clinical Trial to Evaluate the Efficacy of 4-week Treatment With Stillen Tab. in Patients With Acute or Chronic Gastritis Completed NCT01817556 Phase 4 Stillen Tab.;Mucosta Tab.
10 Clinical Effect of Rebamipide on Chronic Gastritis Completed NCT02393430 Phase 4 Rebamipide
11 A Phase 4, Multicenter, Randomized, Open, Active Drug Comparative Trial to Evaluated the Efficacy and Safety of EUPASIDIN-S Tab. in Gastritis Patients Completed NCT02356679 Phase 4 Eupasidin-s Tab;Stillen Tab.
12 Helicobacter Pylori Eradication With Berberine Hydrochloride, Lansoprazole, Amoxicillin and Bismuth Versus Clarithromycin Bismuth, Lansoprazole and Amoxicillin: A Randomized, Open-label, Non-inferiority, Phase Ⅳ Trial Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
13 Helicobacter Pylori Eradication With Berberine Hydrochloride,Esomeprazole,Amoxicillin and Clarithromycin Versus Bismuth,Esomeprazole,Amoxicillin,and Clarithromycin: a Randomized,Open-label, Non-inferiority, Phase Ⅳ Trail Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
14 Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets Completed NCT03857425 Phase 4 Clostridum Butyricum Capsule;Bacillus Coagulans Tablets;Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets
15 Randomized Open Labeled Clinical Trial: a Comparative Study of 10-day High Dose PPI-based Triple Therapy vs. 10-day Sequential Therapy for Helicobacter Pylori Eradication in Functional Dyspepsia Patients Completed NCT01888237 Phase 4 Double dose of PPI;sequence of drug use
16 Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy Completed NCT03609892 Phase 4 Berberine;Amoxicillin;Esomeprazole;Bismuth;Tetracycline;Furazolidone;Esomeprazole;Bismuth
17 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Recruiting NCT02047994 Phase 4 Triple therapy
18 A Randomized Controlled Trial of Triple Therapy With Conventional Proton Pump Inhibitor vs Triple Therapy With Vonoprazan as First Line Therapy for Helicobacter Pylori Gastritis Recruiting NCT03908619 Phase 4 Omeprazole 20mg;Esomeprazole 20mg;Rabeprazole Sodium 20mg;Vonoprazan
19 10 Day Concomitant Versus 14 Day Hybrid Regimen as First Line H. Pylori Eradication Treatment in a High Clarithromycin Resistance Area. A Multicenter Randomized Equivalence Trial Recruiting NCT03592069 Phase 4 10 day concomitant regimen;14 day hybrid regimen
20 Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy Not yet recruiting NCT04678492 Phase 4 Esomeprazole;Amoxicillin;Bismuth;Esomeprazole;Tetracycline;Furazolidone
21 Efficacy and Safety of Berberine Hydrochloride, Amoxicillin and Rabeprazole Triple Therapy in the First Eradication of Helicobacter Pylori Not yet recruiting NCT04697186 Phase 4 Berberine;Amoxicillin;Rabeprazole;Amoxicillin;Clarithromycin;Rabeprazole;Bismuth
22 Delineation of Therapeutic Potential and the Causal Relationship Between Vitamin D and Helicobacter Pylori (HP) Infection and Gastritis Unknown status NCT03142620 Phase 3 Esomeprazole;Amoxicillin-Potassium Clavulanate Combination;Clarithromycin;Vitamin D3
23 Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on the Efficacy of Esomeprazole Treatment for Patients With Lymphocytic Gastritis Unknown status NCT00455754 Phase 3 Esomeprazole
24 A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 Compared With Rebamipide in Patients With Acute or Chronic Gastritis Unknown status NCT01813812 Phase 3 DA-6034;Rebamipide 300mg
25 A Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-5204 and to Demonstrate the Non-inferiority of DA-5204 Compared With Stillen Tab. in Patients With Acute or Chronic Gastritis Unknown status NCT02282670 Phase 3 DA-5204;Stillen tab.
26 Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori Unknown status NCT02422706 Phase 3 Nitazoxanide;Metronidazole(MTZ);Omeprazole;Clarithromycin;Levofloxacin;Doxicycline
27 Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection Unknown status NCT00197418 Phase 2, Phase 3 rabeprazole, amoxicillin, clarithromycin, metronidazole
28 Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection Unknown status NCT00455806 Phase 3 esomeprazole;moxifloxacin;amoxicillin
29 Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori Unknown status NCT00149084 Phase 3 Lansoprazole, clarithromycin, amoxicillin
30 Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis Completed NCT00996788 Phase 3 Rebamipide
31 A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase 3 Clinical Trial to Evaluated the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients Completed NCT03443804 Phase 3 Test(DW1401);Reference(Stillen tab.)
32 Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (The GUARD Study) Completed NCT02246439 Phase 3 RHB-102;Placebo Oral Tablet
33 A Randomized, Double-blinded, Active Controlled, Non-Inferiority, Multicenter, Phase III Clinical Trial to Evaluate the Efficacy and Safety of AD-203 in Patients With Acute or Chronic Gastritis Completed NCT04066530 Phase 3 AD-203;Mucosta tab.
34 Helicobacter Pylori Eradication in Mexico With a Levofloxacin-containing Scheme Versus Clarithromycin-based Triple Therapy: a Randomized, Open-label, Non-inferiority, Phase 3b Trial. Completed NCT02726269 Phase 3 CLA (Clarithro+Lanso+Amoxi);PLA (Panto+Levoflox+Azithro)
35 Comparison of Dual Amoxicillin/Vonoprazan Therapy and Triple Vonoprazan/Amoxicillin/Clarithromycin or Metronidazole Therapy for H. Pylori Eradication Completed NCT02827942 Phase 3 vonoprazan 20 mg bid;Amoxicillin 500 mg tid;Amoxicillin 750 mg bid;Clarithromycin 200 mg bid;Metronidazole 250 mg bid
36 Residual Gastric Volume Measured by Upper Digestive Endoscopy 2h After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein. A Controlled, Randomized Clinical Trial Completed NCT01828645 Phase 2, Phase 3
37 High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment Completed NCT00132171 Phase 3 Sequential therapy
38 Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases: A Prospective Self-controlled Comparative Multicenter Trial Completed NCT02219529 Phase 3
39 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Recruiting NCT04322604 Phase 3 lirentelimab (AK002)
40 A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis Recruiting NCT04255589 Phase 3 CKD-495 75mg;Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg;Placebo of the CKD-495 75mg;Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
41 A Double-Blind, Placebo-controlled Clinical Trial to Evaluate Efficacy of Benralizumab in Subjects With Eosinophilic Gastritis Active, not recruiting NCT03473977 Phase 2, Phase 3
42 A Multi-Center, Double-blind, Randomized, Placebo-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis Enrolling by invitation NCT04341454 Phase 3 DWP14012 X mg;DWP14012 X mg placebo;DWP14012 Y mg;DWP14012 Y mg placebo
43 A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Enrolling by invitation NCT04620811 Phase 3 lirentelimab
44 Evaluation of Topical Rebamipide Versus Topical Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients: Randomized-Controlled Clinical Trial Not yet recruiting NCT04649697 Phase 3 Rebamipide;Nanoparticulated Rebamipide;Clobetasol Propionate
45 A Multi-center, Randomized, Double-blind, Active-controlled, Non-inferiority, Phase 3 Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis Not yet recruiting NCT04189705 Phase 3 MCT-SR;Mucosta Tab.
46 EFFICACY OF ORAL AROEIRA (Schinus Terebinthifolius Raddi), AMOXYCILLIN AND CLARITROMYCIN COMPARED WITH CONVENTIONAL TRIPLE THERAPY FOR Helicobacter Pylori ERADICATION IN GASTRITE AND SYMPTOM PATIENTS: A RANDOMIZED AND DOUBLE-BLIND STUDY Not yet recruiting NCT04069286 Phase 2, Phase 3 Oral Aroeira/ Amoxicillin/ Claritromycin;Omeprazole/ Amoxicillin/ Claritromycin
47 Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection Not yet recruiting NCT04652284 Phase 3 Rifabutin;Amoxicillin;Esomeprazole;Clarithromycin;Tinidazole
48 A Multi-Center, Randomized, Parallel, Double-Blind, Phase III Clinical Trial to Compare the Efficacy and Safety of DWC20155/DWC20156 Combination Therapy With DWC20155 or DWC20156 Monotherapy in Patients With Gastritis Terminated NCT03184415 Phase 3 DWC20155;DWC20156;placebo of DWC20155;placebo of DWC20156
49 Double Blind, Multicenter, Randomized, Placebo-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis Unknown status NCT02353039 Phase 2 GC6101A 37.5mg;GC6101A 75mg;GC6101A 150mg;Placebo
50 Open Label, Randomized, Single Site Clinical Trial To Compare The Safety Of Herbal Melanin Extracted From Nigella Sativa Seeds Vs Standard Of Care Treatment In Treating Gastritis Patients Unknown status NCT03428568 Phase 2 Nexium;Amoxil;Clarithromycin

Search NIH Clinical Center for Gastritis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cat's Claw preparation
Sucralfate

Cochrane evidence based reviews: gastritis

Genetic Tests for Gastritis

Genetic tests related to Gastritis:

# Genetic test Affiliating Genes
1 Gastritis 29

Anatomical Context for Gastritis

MalaCards organs/tissues related to Gastritis:

40
T Cells, Neutrophil, Pancreas, Spleen, Endothelial, Tongue, Thyroid

Publications for Gastritis

Articles related to Gastritis:

(show top 50) (show all 22034)
# Title Authors PMID Year
1
Defensin-mRNA expression in the upper gastrointestinal tract is modulated in children with celiac disease and Helicobacter pylori-positive gastritis. 54 61
20400909 2010
2
Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model. 54 61
20026064 2010
3
Prevalence of Helicobacter pylori vacA, cagA, iceA and oipA genotypes in Tunisian patients. 54 61
20302630 2010
4
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. 61 54
19711347 2010
5
In situ expression of cagA and risk of gastroduodenal disease in Helicobacter pylori-infected children. 54 61
20038850 2010
6
TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis. 54 61
20332463 2010
7
Interleukin 1 beta (IL1B) gene polymorphisms are not associated with gastric carcinogenesis in Germany. 61 54
20332462 2010
8
[Quantification of cyclooxygenase-2 methylation in gastric mucosa by denaturing high performance liquid chromatography assay]. 61 54
20388365 2010
9
Gastrin induces the interaction between human mononuclear leukocytes and endothelial cells through the endothelial expression of P-selectin and VCAM-1. 61 54
19812370 2009
10
Gastric ghrelin in relation to gender, stomach topography and Helicobacter pylori in dyspeptic patients. 61 54
19916170 2009
11
RANTES promoter genotype and gastric cancer risk in a Japanese population. 61 54
19846984 2009
12
homB status of Helicobacter pylori as a novel marker to distinguish gastric cancer from duodenal ulcer. 54 61
19710266 2009
13
Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori-positive API2-MALT1-negative gastric MALT lymphoma. 61 54
19385974 2009
14
Transforming growth factor-B1 and matrix metalloproteinase-7 promoter variants induce risk for Helicobacter pylori-associated gastric precancerous lesions. 54 61
19317620 2009
15
Remnant gastritis should be evaluated histologically rather than endoscopically. 61 54
19621726 2009
16
A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. 54 61
19262506 2009
17
Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study. 61 54
19399945 2009
18
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 61 54
18612816 2009
19
Gender difference of circulating ghrelin and leptin concentrations in chronic Helicobacter pylori infection. 54 61
19191897 2009
20
Iron deficiency, Helicobacter infection and gastritis. 54 61
19907146 2009
21
Role of cyclooxygenase-2 functional gene polymorphisms in Helicobacter pylori induced gastritis and gastric atrophy. 61 54
18825488 2009
22
Potential role of human beta-defensin 1 in Helicobacter pylori-induced gastritis. 54 61
18991164 2009
23
[Dynamics of pro-and anti-inflammatory cytokines at patients with combination of chronic opisthorchiasis with Helicobacter pylori-associated gastritis]. 54 61
19551959 2009
24
Cross-talk between inducible nitric oxide synthase and cyclooxygenase in Helicobacter-pylori-induced gastritis. 54 61
19797925 2009
25
The relationship between virulence factors of Helicobacter pylori and severity of gastritis in infected patients. 54 61
18465229 2009
26
Decreased TFF2 expression in the gastric antrum in patients infected with CagA-positive Helicobacter pylori. 61 54
19344006 2009
27
Prevalence of Helicobacter pylori pathogenicity-associated cagA and vacA genotypes among Pakistani dyspeptic patients. 61 54
19040660 2009
28
Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer. 54 61
18985541 2009
29
Bile acid induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human gastric cancer cells. 61 54
18775915 2008
30
The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype--a link to gastric carcinogenesis. 54 61
18571838 2008
31
Presence of poorly differentiated component correlated with submucosal invasion in the early diffuse-type gastric cancer. 61 54
19260519 2008
32
cagA, vacA, and iceA genotypes of Helicobacter pylori in Korean children. 61 54
19261108 2008
33
Helicobacter pylori infection induces a reversible expression of the CDX2 transcription factor protein in human gastric epithelium. 61 54
19086163 2008
34
vacA genotypes of Helicobacter pylori in relation to cagA status and clinical outcomes in Iranian populations. 54 61
18653971 2008
35
Serum gastrin concentration and changes in G and D cell densities in gastric antrum in children with chronic gastritis. 54 61
17573842 2008
36
Toll-like receptor 2 (TLR) -196 to 174del polymorphism in gastro-duodenal diseases in Japanese population. 61 54
17934843 2008
37
Four modes of adhesion are used during Helicobacter pylori binding to human mucins in the oral and gastric niches. 54 61
18321298 2008
38
The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. 54 61
18321304 2008
39
IL-4 -588C>T polymorphism and IL-4 receptor alpha [Ex5+14A>G; Ex11+828A>G] haplotype concur in selecting H. pylori cagA subtype infections. 61 54
18179773 2008
40
T-251A polymorphism of IL-8 relating to the development of histological gastritis and G-308A polymorphism of TNF-alpha relating to the development of macroscopic erosion. 54 61
18301299 2008
41
Expression of 8-hydroxydeoxyguanosine in the gastric remnant after distal gastrectomy. 54 61
18613397 2008
42
Long-term effects of Helicobacter pylori eradication on circulating ghrelin and leptin concentrations and body composition in prepubertal children. 61 54
18299465 2008
43
Autoimmune gastritis in type 1 diabetes: a clinically oriented review. 61 54
18029461 2008
44
Is interleukin-1 genotyping useful for the clinical management of patients with atrophic body gastritis? 61 54
18047563 2008
45
Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. 54 61
18237867 2008
46
Microevolution of Helicobacter pylori type IV secretion systems in an ulcer disease patient over a ten-year period. 54 61
17942650 2007
47
Emergence of spasmolytic polypeptide-expressing metaplasia in Mongolian gerbils infected with Helicobacter pylori. 54 61
18004396 2007
48
Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. 54 61
17948927 2007
49
Association of Toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. 54 61
18082569 2007
50
Preferential induction of transforming growth factor-beta production in gastric epithelial cells and monocytes by Helicobacter pylori soluble proteins. 61 54
17922404 2007

Variations for Gastritis

ClinVar genetic disease variations for Gastritis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro) SNV Uncertain significance 128688 rs587780309 9:135946855-135946855 9:133071468-133071468

Expression for Gastritis

Search GEO for disease gene expression data for Gastritis.

Pathways for Gastritis

Pathways related to Gastritis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 TLR4 S100A8 PTGS2 NOS2 MUC6 IL1RN
2
Show member pathways
12.59 TLR4 PTGS2 NOS2 IL1RN IL1B CXCL8
3
Show member pathways
12.24 S100A8 DEFB1 DEFA5 CHGA
4
Show member pathways
12.2 TLR4 PTGS2 NOS2 IL1B CXCL8
5
Show member pathways
12.19 S100A8 PTGS2 IL1B CXCL8 CXCL1
6
Show member pathways
12.18 TLR4 PTGS2 NOS2 IL1B
7
Show member pathways
12.09 TLR4 NOS2 IL1B CXCL8
8 12.06 TLR4 IL1B DEFA5 CXCL8 CXCL1
9 11.88 PTGS2 NOS2 IL1B CXCL8
10
Show member pathways
11.76 TLR4 CXCL8 CXCL1
11 11.76 TLR4 IL1B CXCL8 CXCL1
12 11.67 TLR4 PTGS2 IL1B CXCL8 CXCL1
13 11.61 TLR4 NOS2 IL1B CXCL8
14 11.56 TLR4 NOS2 IL1B CXCL8 CXCL1
15 11.48 PTGS2 NOS2 CXCL8
16
Show member pathways
11.47 PTGS2 NOS2 IL1B CXCL8
17 11.46 TLR4 IL1B CXCL8
18 11.42 TLR4 NOS2 IL1B
19 11.38 TLR4 IL1B CXCL8 CXCL1
20
Show member pathways
11.36 PGA5 PGA4 PGA3
21 11.18 TLR4 PTGS2 NOS2 IL1B CXCL8 CXCL1
22 11.04 PTGS2 IL1RN IL1B CXCL8 CXCL1
23 10.45 MUC6 GAST
24 10.27 HRH2 GAST

GO Terms for Gastritis

Cellular components related to Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 TFF2 S100A8 PGC MUC6 IL1RN IL1B
2 extracellular region GO:0005576 9.53 TFF2 S100A8 PGC PGA5 PGA4 PGA3
3 Golgi lumen GO:0005796 9.43 MUC6 DEFB1 DEFA5
4 multivesicular body lumen GO:0097486 9.33 PGA5 PGA4 PGA3

Biological processes related to Gastritis according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.91 TLR4 IL1RN IL1B HRH2 DEFB1 CXCL8
2 cytokine-mediated signaling pathway GO:0019221 9.88 PTGS2 NOS2 IL1RN IL1B CXCL8 CXCL1
3 chemotaxis GO:0006935 9.85 S100A8 DEFB1 CXCL8 CXCL1
4 response to lipopolysaccharide GO:0032496 9.85 TLR4 S100A8 PTGS2 NOS2 IL1B
5 defense response GO:0006952 9.84 DEFB1 DEFA5 CXCL8 CXCL1
6 positive regulation of inflammatory response GO:0050729 9.8 TLR4 S100A8 IL1B
7 defense response to bacterium GO:0042742 9.8 TLR4 S100A8 NOS2 DEFB1 DEFA5 CHGA
8 regulation of inflammatory response GO:0050727 9.79 TLR4 S100A8 PTGS2
9 cellular response to mechanical stimulus GO:0071260 9.79 TLR4 PTGS2 IL1B
10 neutrophil chemotaxis GO:0030593 9.78 S100A8 CXCL8 CXCL1
11 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.78 DEFB1 DEFA5 CXCL8 CXCL1
12 chemokine-mediated signaling pathway GO:0070098 9.77 TFF2 CXCL8 CXCL1
13 antimicrobial humoral response GO:0019730 9.73 S100A8 DEFB1 DEFA5 CHGA
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 TLR4 PTGS2 IL1B
15 defense response to fungus GO:0050832 9.69 S100A8 DEFA5 CHGA
16 innate immune response in mucosa GO:0002227 9.67 NOS2 DEFB1 DEFA5
17 maintenance of gastrointestinal epithelium GO:0030277 9.63 TFF2 MUC6
18 gastric acid secretion GO:0001696 9.59 HRH2 GHRL
19 negative regulation of blood vessel diameter GO:0097756 9.58 PTGS2 CHGA
20 positive regulation of prostaglandin biosynthetic process GO:0031394 9.58 PTGS2 IL1B
21 positive regulation of fever generation GO:0031622 9.57 PTGS2 IL1B
22 peptidyl-cysteine S-nitrosylation GO:0018119 9.56 S100A8 NOS2
23 digestion GO:0007586 9.56 PGC PGA5 PGA4 PGA3
24 defense response to Gram-negative bacterium GO:0050829 9.55 TLR4 NOS2 DEFB1 DEFA5 CHGA
25 cellular response to lipopolysaccharide GO:0071222 9.43 TLR4 NOS2 IL1B DEFA5 CXCL8 CXCL1
26 inflammatory response GO:0006954 9.23 TLR4 S100A8 PTGS2 NOS2 IL1RN IL1B

Molecular functions related to Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CXCR chemokine receptor binding GO:0045236 9.26 CXCL8 CXCL1
2 cytokine activity GO:0005125 9.26 IL1RN IL1B CXCL8 CXCL1
3 interleukin-1 receptor binding GO:0005149 9.16 IL1RN IL1B
4 aspartic-type endopeptidase activity GO:0004190 8.92 PGC PGA5 PGA4 PGA3

Sources for Gastritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....